Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesKymera Therapeutics Inc

Kymera Therapeutics Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
138.86 USD 7.13 ( 5.41%)
Last update at 2026-11-09T21:05:00Z
VOLUME
1262786
Market Cap
9408.49M

Momentum Score

…

Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing KT-621, an oral STAT6 degrader in Phase 2b clinical trials for moderate to severe atopic dermatitis, asthma, COPD, EoE, CRSwNP, CSU, PN, BP, and others; KT-579, an oral IRF5 degrader in Phase 1 trials for autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, SSc, DM, and others; KT-485/SAR447971, IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis; and cyclin-dependent kinase 2 (CDK2) with broad oncology treatment potential, including in breast cancer and other solid tumors. The company has a strategic alliance with Sanofi S.A. for the development of drug candidates targeting IRAK4 outside the oncology and immuno-oncology fields. Kymera Therapeutics, Inc. was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
130.79
Low
140.67
High
52 Week Price Range
47.90
Low
130.05
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Kymera Therapeutics is a clinical-stage biopharmaceutical company developing targeted protein degraders with a proprietary discovery platform to address immune/inflammatory diseases and oncology. Long-term growth drivers include clinical validation of the platform, advancement of lead candidates, and strategic partnerships that may support development and commercialization, offering investors exposure to a modality that could target previously undruggable proteins.

Investors should monitor clinical and regulatory uncertainty for a novel modality, continued need for financing while unprofitable, and competitive and intellectual-property pressures.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
131.73
Dividend Yield
-
Revenue TTM
105.00M
Revenue Per Share
1.13
Gross Profit TTM
-270.57M
Debt / Equity
0.05
ROE
-24.15%
Net Debt
-274.76M
ROCE
-18.76%
Diluted EPS TTM
-3.21

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -311.62M -223.86M -146.96M -154.81M -100.22M
Net income -311.40M -223.86M -146.96M -151.83M -98.00M
Selling general administrative 68.20M 63.53M 55.04M 43.83M 36.34M
Gross profit 39.20M 47.07M 78.59M 46.83M 72.83M
Reconciled depreciation 8.31M 7.37M 3.56M 2.98M 2.40M
Ebit -311.37M -223.61M -146.77M -161.26M -100.53M
Ebitda -303.06M -216.24M -143.20M -154.63M -100.04M
Depreciation and amortization 8.31M 7.37M 3.56M 6.62M 0.49M
Non operating income net other - - - 6.45M 0.31M
Operating income -349.40M -261.63M -165.53M -161.26M -100.53M
Other operating expenses 388.60M 308.71M 244.12M 208.08M 173.36M
Interest expense 0.25M 0.25M 0.20M 0.18M 0.17M
Interest income 38.42M 38.03M 18.76M 6.62M 0.49M
Net interest income 38.05M 37.78M 18.57M 6.45M 0.31M
Income tax expense - - 18.76M -2.98M -2.22M
Total revenue 39.20M 47.07M 78.59M 46.83M 72.83M
Total operating expenses 388.60M 308.71M 244.12M 208.08M 173.36M
Cost of revenue - 7.37M 189.08M - -
Total other income expense net 37.78M 37.78M 18.57M 6.45M 0.31M
Net income from continuing ops -311.35M -223.86M -146.96M -154.81M -100.22M
Net income applicable to common shares - - - -154.81M -100.22M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 1742.81M 978.03M 575.76M 603.13M 605.90M
Other current assets 22.94M 20.58M 11.67M 9.71M 8.86M
Total liab 163.15M 142.42M 180.79M 112.98M 146.27M
Total stockholder equity 1579.66M 835.62M 394.97M 490.15M 459.64M
Other current liab 42.52M 35.09M 34.39M -8.28M -7.60M
Common stock 0.01M 0.01M 0.01M 0.01M 0.01M
Capital stock 0.01M 0.01M 0.01M 0.01M 0.01M
Retained earnings -1065.96M -754.61M -530.75M -383.79M -228.98M
Other liab - - - 28.25M 39.36M
Other assets - - - 9.15M 8.14M
Cash 357.01M 120.26M 109.97M 68.39M 47.98M
Total current liabilities 83.21M 67.77M 85.69M 63.26M 101.03M
Current deferred revenue 22.93M 13.58M 37.88M 63.26M 101.03M
Net debt -274.76M -32.49M -25.29M -51.06M -30.01M
Short term debt 13.76M 13.11M 6.34M 3.94M 3.60M
Short long term debt total 82.25M 87.76M 84.67M 17.34M 17.96M
Other stockholder equity 2643.82M 1591.71M 926.27M 878.88M 689.27M
Property plant equipment - - - 13.33M 11.88M
Total current assets 871.21M 510.27M 405.32M 559.49M 567.61M
Long term investments 771.16M 362.16M 61.43M 152.33M 125.19M
Net tangible assets - - - 490.15M 459.64M
Short term investments 491.26M 368.49M 264.92M 338.77M 394.44M
Net receivables - 0.95M 18.76M 2.54M 0.14M
Inventory - - 0.00M -12.25M -8.99M
Accounts payable 4.01M 5.99M 7.08M 4.33M 4.00M
Accumulated other comprehensive income 1.80M -1.49M -0.55M -4.95M -0.66M
Common stock total equity - - - 0.01M 0.01M
Retained earnings total equity - - - -383.79M -228.98M
Non currrent assets other 9.11M 7.74M 7.93M -122.02M -98.77M
Non current assets total 871.60M 467.77M 170.44M 43.64M 38.30M
Capital lease obligations 82.25M 87.76M 84.67M 17.34M 17.96M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments -519.61M -404.08M 71.27M 20.52M -98.24M
Change to liabilities - - - 5.03M 12.74M
Total cashflows from investing activities -521.06M -404.08M 139.89M 20.52M -99.83M
Net borrowings -1.49M -1.58M -0.08M -1.13M -0.85M
Total cash from financing activities 990.71M 608.85M 4.19M 153.00M 250.28M
Change to operating activities - - - 2.30M 6.08M
Net income -311.35M -223.86M -146.96M -154.81M -100.22M
Change in cash 236.76M 10.27M 41.25M 20.43M 21.50M
Begin period cash flow 126.05M 115.78M 74.53M 54.09M 32.59M
End period cash flow 362.81M 126.05M 115.78M 74.53M 54.09M
Total cash from operating activities -232.89M -194.50M -102.83M -153.09M -128.95M
Issuance of capital stock 928.90M 596.62M 0.00M 149.82M 243.11M
Depreciation 8.31M 7.37M 3.56M 2.98M 2.40M
Other cashflows from investing activities 8.88M 13.98M 174.37M - -
Change to inventory - - 23.37M - 8.71M
Change to account receivables 0.95M 17.82M -16.23M -2.40M 0.58M
Sale purchase of stock - - - 4.30M 8.02M
Other cashflows from financing activities 990.71M 13.81M 4.27M 4.30M 8.02M
Change to netincome - - - 35.48M 24.99M
Capital expenditures 1.45M 12.84M 34.48M 2.84M 1.60M
Change receivables - - - - 0.58M
Cash flows other operating - - - -41.76M -69.43M
Cash and cash equivalents changes - - - 20.43M 21.50M
Change in working capital 15.27M -23.97M 9.25M -37.62M -61.92M
Stock based compensation 59.90M 55.01M 43.12M 35.48M 24.97M
Other non cash items -5.02M -9.06M -11.80M 0.89M 5.83M
Free cash flow -234.34M -207.34M -137.31M -155.92M -130.54M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
KYMR
Kymera Therapeutics Inc		 7.13
5.41%		 138.86 - - 88.64 6.32 85.06 -9.49
NVO
Novo Nordisk A/S		 1.09
2.72%		 41.41 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 3.78
0.69%		 550.87 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 15.61
1.73%		 919.96 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Kymera Therapeutics Inc

Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing KT-621, an oral STAT6 degrader in Phase 2b clinical trials for moderate to severe atopic dermatitis, asthma, COPD, EoE, CRSwNP, CSU, PN, BP, and others; KT-579, an oral IRF5 degrader in Phase 1 trials for autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, SSc, DM, and others; KT-485/SAR447971, IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis; and cyclin-dependent kinase 2 (CDK2) with broad oncology treatment potential, including in breast cancer and other solid tumors. The company has a strategic alliance with Sanofi S.A. for the development of drug candidates targeting IRAK4 outside the oncology and immuno-oncology fields. Kymera Therapeutics, Inc. was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

500 North Beacon Street, Watertown, MA, United States, 02472

857 285 5300

https://www.kymeratx.com

273

Name Title Year Born
Dr. Bruce L. Booth D.Phil., DPHIL, Ph.D. Co-Founder & Chairman 1974
Dr. Nello Mainolfi M.D., Ph.D. Co-Founder, Pres, CEO & Director 1979
Mr. Bruce N. Jacobs CFA Chief Financial Officer NA
Dr. Jared A. Gollob M.D. Chief Medical Officer 1965
Ms. Elaine Caughey Chief Bus. Officer NA
Kevin Dushney Sr. VP of IT & Operations NA
Mr. Michael J. Todisco VP of Accounting & Fin. 1965
Mr. Vijay Sabesan Sr. VP of Technical Operations 1972
Ms. Melissa Brody VP of Bus. Devel. NA
Ms. Karen Weisbach VP of People & Culture NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

GFR
CAD 10.94
+37.96%
MOON
CAD 5.04
+14.17%
FDY
CAD 4.42
+12.18%
UCU
CAD 2.38
+11.21%
PDN
CAD 8.39
+11.13%
DIV
CAD 3.64
-10.57%
TOI
CAD 99.55
-4.99%
BSX
CAD 0.82
-4.65%
CSU
CAD 3367.07
-4.52%
LMN
CAD 26.82
-4.52%

Equity Sectors*

  • Basic Materials

    +5.01%

  • Communication Services

    -0.62%

  • Consumer Cyclical

    +1.25%

  • Consumer Defensive

    +0.14%

  • Energy

    +1.86%

  • Financial Services

    +1.87%

  • Healthcare

    +1.10%

  • Industrials

    +3.75%

  • Real Estate

    +0.53%

  • Technology

    +2.31%

  • Utilities

    +0.99%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…